S&P 500   3,757.94 (-0.67%)
DOW   30,008.77 (-0.88%)
QQQ   281.90 (-0.03%)
AAPL   146.46 (+0.04%)
MSFT   248.36 (-0.34%)
META   141.20 (+1.60%)
GOOGL   102.16 (+0.72%)
AMZN   120.88 (-0.06%)
TSLA   241.77 (+0.40%)
NVDA   133.32 (+0.93%)
NIO   14.97 (-6.67%)
BABA   85.03 (+0.76%)
AMD   68.88 (+1.38%)
T   15.46 (-2.95%)
MU   54.82 (+0.16%)
CGC   2.98 (-2.93%)
F   12.47 (-0.32%)
GE   66.25 (-1.76%)
DIS   101.06 (+0.26%)
AMC   7.34 (+0.14%)
PYPL   94.81 (+1.04%)
PFE   43.31 (-1.84%)
NFLX   242.66 (+2.50%)
S&P 500   3,757.94 (-0.67%)
DOW   30,008.77 (-0.88%)
QQQ   281.90 (-0.03%)
AAPL   146.46 (+0.04%)
MSFT   248.36 (-0.34%)
META   141.20 (+1.60%)
GOOGL   102.16 (+0.72%)
AMZN   120.88 (-0.06%)
TSLA   241.77 (+0.40%)
NVDA   133.32 (+0.93%)
NIO   14.97 (-6.67%)
BABA   85.03 (+0.76%)
AMD   68.88 (+1.38%)
T   15.46 (-2.95%)
MU   54.82 (+0.16%)
CGC   2.98 (-2.93%)
F   12.47 (-0.32%)
GE   66.25 (-1.76%)
DIS   101.06 (+0.26%)
AMC   7.34 (+0.14%)
PYPL   94.81 (+1.04%)
PFE   43.31 (-1.84%)
NFLX   242.66 (+2.50%)
S&P 500   3,757.94 (-0.67%)
DOW   30,008.77 (-0.88%)
QQQ   281.90 (-0.03%)
AAPL   146.46 (+0.04%)
MSFT   248.36 (-0.34%)
META   141.20 (+1.60%)
GOOGL   102.16 (+0.72%)
AMZN   120.88 (-0.06%)
TSLA   241.77 (+0.40%)
NVDA   133.32 (+0.93%)
NIO   14.97 (-6.67%)
BABA   85.03 (+0.76%)
AMD   68.88 (+1.38%)
T   15.46 (-2.95%)
MU   54.82 (+0.16%)
CGC   2.98 (-2.93%)
F   12.47 (-0.32%)
GE   66.25 (-1.76%)
DIS   101.06 (+0.26%)
AMC   7.34 (+0.14%)
PYPL   94.81 (+1.04%)
PFE   43.31 (-1.84%)
NFLX   242.66 (+2.50%)
S&P 500   3,757.94 (-0.67%)
DOW   30,008.77 (-0.88%)
QQQ   281.90 (-0.03%)
AAPL   146.46 (+0.04%)
MSFT   248.36 (-0.34%)
META   141.20 (+1.60%)
GOOGL   102.16 (+0.72%)
AMZN   120.88 (-0.06%)
TSLA   241.77 (+0.40%)
NVDA   133.32 (+0.93%)
NIO   14.97 (-6.67%)
BABA   85.03 (+0.76%)
AMD   68.88 (+1.38%)
T   15.46 (-2.95%)
MU   54.82 (+0.16%)
CGC   2.98 (-2.93%)
F   12.47 (-0.32%)
GE   66.25 (-1.76%)
DIS   101.06 (+0.26%)
AMC   7.34 (+0.14%)
PYPL   94.81 (+1.04%)
PFE   43.31 (-1.84%)
NFLX   242.66 (+2.50%)
NASDAQ:VRNA

Verona Pharma - VRNA Stock Forecast, Price & News

$10.52
-0.08 (-0.75%)
(As of 10/6/2022 01:55 PM ET)
Add
Compare
Today's Range
$10.22
$10.63
50-Day Range
$5.38
$13.59
52-Week Range
$3.41
$14.69
Volume
3,312 shs
Average Volume
285,977 shs
Market Capitalization
$765.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.75

Verona Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
176.7% Upside
$28.75 Price Target
Short Interest
Healthy
1.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$1.10 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.33) to ($1.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

688th out of 1,072 stocks

Pharmaceutical Preparations Industry

329th out of 534 stocks

VRNA stock logo

About Verona Pharma (NASDAQ:VRNA) Stock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Stock News Headlines

Small-Cap Catalyst Pharma Is Among Market's Best Price Performers (VRNA)
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.
Verona Pharma (NASDAQ:VRNA) Trading Up 6.6%
VRNA Verona Pharma plc
Dow Drops Over 100 Points; Verona Pharma Shares Jump
Recap: Verona Pharma Q2 Earnings
Why Verona Pharma Stock Is Skyrocketing Today
See More Headlines
Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Company Calendar

Last Earnings
8/09/2022
Today
10/06/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRNA
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.75
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+173.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-55,570,000.00
Pretax Margin
-136.94%

Debt

Sales & Book Value

Annual Sales
$40 million
Book Value
$2.47 per share

Miscellaneous

Free Float
69,930,000
Market Cap
$765.54 million
Optionable
Not Optionable
Beta
0.43

Key Executives

  • Dr. David S. ZaccardelliDr. David S. Zaccardelli (Age 57)
    Pres, CEO & Exec. Director
    Comp: $627.27k
  • Mr. Mark W. HahnMr. Mark W. Hahn (Age 59)
    Chief Financial Officer
    Comp: $639.08k
  • Dr. Kathleen A. Rickard (Age 64)
    Chief Medical Officer
    Comp: $562.38k
  • Ms. Claire Louise Poll L.C.S.W. (Age 55)
    B.A., B Juris, LLB, ASIA, Gen. Counsel
  • Ms. Victoria Stewart
    Director of Communications
  • Mr. Matthew Casbon
    VP of Sales, Marketing & Training
  • Dr. Peter Spargo (Age 60)
    Sr. VP of Chemistry Manufacturing & Controls
  • Dr. Tara Rheault M.P.H. (Age 45)
    Ph.D., Sr. VP of R&D
  • Ms. Nina Church
    Exec. Director of Global Clinical Devel.
  • Mr. Christopher Martin
    Sr. VP of Commercial













VRNA Stock - Frequently Asked Questions

Should I buy or sell Verona Pharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings
or view top-rated stocks.

What is Verona Pharma's stock price forecast for 2022?

4 equities research analysts have issued twelve-month price objectives for Verona Pharma's stock. Their VRNA share price forecasts range from $27.00 to $31.00. On average, they anticipate the company's share price to reach $28.75 in the next year. This suggests a possible upside of 174.3% from the stock's current price.
View analysts price targets for VRNA
or view top-rated stocks among Wall Street analysts.

How have VRNA shares performed in 2022?

Verona Pharma's stock was trading at $6.72 at the start of the year. Since then, VRNA shares have increased by 56.0% and is now trading at $10.48.
View the best growth stocks for 2022 here
.

When is Verona Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our VRNA earnings forecast
.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) released its earnings results on Tuesday, August, 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $10.48.

How much money does Verona Pharma make?

Verona Pharma (NASDAQ:VRNA) has a market capitalization of $762.63 million and generates $40 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com.

This page (NASDAQ:VRNA) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.